Press Releases June 19, 2025: MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025 Marketing Authorization…MaaT PharmaJune 19, 2025
Press Releases June 13, 2025: MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress Validating High Efficacy Observed in Pivotal ARES Study in Acute Graft-versus-Host Disease MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA…MaaT PharmaJune 13, 2025
Press Releases June 2, 2025: MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg® (MaaT013) in Acute Graft-versus-Host Disease MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency…MaaT PharmaJune 2, 2025
Press Releases May 14, 2025: MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European Hematology Association (EHA) Annual Congress MaaT Pharma To Present Updated Data for MaaT013 in Early Access Program at the European…MaaT PharmaMay 14, 2025
Press Releases April 28, 2025: MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity of MaaT034 MaaT Pharma Presents Preclinical Data at AACR Annual Meeting Demonstrating Immune Activation and Anti-Tumor Activity…MaaT PharmaApril 28, 2025
Press Releases April 14, 2025: Availability of MaaT Pharma’s 2024 Universal Registration Document (URD) Availability of MaaT Pharma’s 2024 Universal Registration Document (URD) Lyon, France, April 14, 2025 -…MaaT PharmaApril 14, 2025
Press Releases April 8, 2025: MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033 for Patients Receiving Allo-HSCT MaaT Pharma Announces Positive Safety Interim Analysis from DSMB for Phase 2b Trial Evaluating MaaT033…MaaT PharmaApril 8, 2025
Press Releases April 4, 2025: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital…MaaT PharmaApril 4, 2025
Press Releases March 31, 2025: MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve…MaaT PharmaMarch 31, 2025
Press Releases March 18, 2025: MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial Evaluating MaaT013 in Acute Graft-versus-Host Disease MaaT Pharma Announces Positive Outcomes from Final DSMB Meeting for Pivotal Phase 3 Clinical Trial…MaaT PharmaMarch 18, 2025